collaboration-proxygen-molecular-glue-degraders

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer  New collaboration strengthens Boehringer Ingelheim ’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancersProxygen ’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis targeting chimeras (PROTACs) in the aim of degrading cancer drivers that were previously considered undruggable 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news